Enhanced biopharmaceutical characterization using the SELECT SERIES™ MRT

Importance of the Topic

The emergence of biologics as a major therapeutic class demands advanced analytical tools to ensure their characterization and quality control. Ultra-high resolution and mass accuracy are essential to identify complex molecules, detect post-translational modifications, and confirm molecular integrity in drug development and manufacturing.

Study Objectives and Overview

This whitepaper evaluates the performance of the SELECT SERIES MRT, a novel Q-MRT mass spectrometer, when applied to peptide mapping, subunit analysis, and intact monoclonal antibody (mAb) characterization. It aims to demonstrate how its resolving power and mass accuracy address common challenges in biopharmaceutical analysis.

Methodology and Instrumentation

The study combined liquid chromatography with the SELECT SERIES MRT system. Key elements included:

• Ionization: ESI Lockspray with universal API source and StepWave XS optics
• Mass Analyzer: Hybrid quadrupole and multi-reflecting time-of-flight (Q-MRT) offering >200,000 FWHM
• Chromatography: Waters ACQUITY UPLC I-Class with peptide and protein columns at controlled temperatures
• Data Acquisition: MSE and MS modes using MassLynx v4.2 and UNIFI v1.9 software
• Sample Workflows: Trypsin digestion, IdeS subunit generation, and native/denaturing intact mAb infusion

Key Results and Discussion

The system delivered exceptional performance across three application areas:

• Peptide Mapping: Achieved 98% sequence coverage of NISTmAb with 1 ppm tolerance and RMS error of 485 ppb for precursors, resolving deamidated peptides from their native counterparts.
• Subunit Analysis: Fully resolved isotope patterns for IdeS-generated Fc, Fd, and light chain fragments; deconvolution errors ranged from 0.7 to 2.0 ppm, confirming accurate monoisotopic mass determination.
• Intact mAb Characterization: Employed ‘Diamond’ mode for extended mass range up to 20,000 m/z; produced high-quality spectra for denatured and native NISTmAb, enabling glycoform profiling.

Benefits and Practical Applications

The ultra-high resolution and sub-ppb mass accuracy facilitate:

• Reliable identification of critical quality attributes such as post-translational modifications and low-abundance variants
• Improved confidence in sequence assignments and profile reproducibility
• Streamlined workflows for peptide mapping, middle-up analysis, and intact mass measurement in biopharmaceutical R&D and QC

Future Trends and Opportunities

The integration of ultra-high resolution Q-MRT into routine biopharma analysis paves the way for:

• Automated high-throughput workflows with AI-driven data interpretation
• Expansion into native state and complex assemblies beyond mAbs
• Enhanced multi-omics compatibility and real-time monitoring of bioprocesses

Conclusion

The SELECT SERIES MRT system represents a significant advancement in mass spectrometry for biologics, delivering unmatched resolution and accuracy. Its versatility across peptide, subunit, and intact analyses supports robust characterization strategies, improving data quality and accelerating biopharmaceutical development.